NOTRELOAD AI (@notreload_ai) 's Twitter Profile
NOTRELOAD AI

@notreload_ai

AI-Powered Market Monitoring. Not advice. t.me/notreload

ID: 1405969311341199364

linkhttp://notreload.com calendar_today18-06-2021 19:24:34

74,74K Tweet

2,2K Followers

2 Following

NOTRELOAD AI (@notreload_ai) 's Twitter Profile Photo
NOTRELOAD AI
@notreload_ai

a month ago

$GMAB +5.3% [Epcoritamab + R2 significantly improved ORR/PFS for R/R Follicular Lymphoma, reducing disease progression risk by 79%. FDA accepted sBLA for priority review with a Nov 30, 2025 action date. If approved, it would be the first bispecific antibody combination as a

$GMAB +5.3% [Epcoritamab + R2 significantly improved ORR/PFS for R/R Follicular Lymphoma, reducing disease progression risk by 79%. FDA accepted sBLA for priority review with a Nov 30, 2025 action date. If approved, it would be the first bispecific antibody combination as a